Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + M9241 dose-finding study in advanced solid tumors
NL-OMON48631Phase 1Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of avelumab and NHS-IL-12 in Nonhematologic neoplasms, transitional cell carcinoma (TCC), non-small cell lung cancer (NSCLC) and 2 more (5 arms), sponsored by Merck KGaA. Primary endpoints: Confirmed best overall response and Safety and tolerability. Started Oct 2018; status: active, not recruiting.
02
Drugs
avelumabNHS-IL-12
03
Conditions
Nonhematologic neoplasmstransitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON48631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48631.